Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

Alessandro Russo, MD1,2; David Arias Ron, MD3; Marika Rasschaert, MD3; Hans Prenen, MD, PhD3; Ranee Mehra, MD1; Katherine Scilla, MD1; Patrick Pauwels, PhD3; and Christian Rolfo, MD, PhD, MBA, DrHC1,3 Show More 1University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, Baltimore, MD2A.O. Papardo and University of Messina, Messina, Italy3University Hospital…

Read the full article here

Source: JCO Precision Oncology

Categories: Hem/Onc News and Journals

Tags: lcsm

Tweets with this article

ASCO Publications

Pazopanib in refractory FGFR1-amplified small cell lung cancer. https://t.co/3U72sq8mtl #lcsm #JCOPO https://t.co/IviN8LEXWW

Did I Mess Up Today? Relief and Regret After Deciding to Hang Up My Stethoscope | ASCO Publications

Listen to JCO Oncology Practice’s Art of Oncology Practice article,

ASCO Publications January 22, 2025

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

PURPOSEERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit…

ASCO Publications January 21, 2025

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…

ASCO Publications January 17, 2025

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…

ASCO Publications January 17, 2025

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

PURPOSETrastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated…

ASCO Publications January 16, 2025

Treatment of Pleural Mesothelioma: ASCO Guideline Update

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…

ASCO Publications January 16, 2025

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

PURPOSENeoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer…

ASCO Publications January 15, 2025

Treatment of Pleural Mesothelioma: ASCO Guideline Update

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…

ASCO Publications January 15, 2025

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier:…

ASCO Publications January 14, 2025

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab…

ASCO Publications January 14, 2025

Related Articles